206,532 Shares in Insmed, Inc. $INSM Bought by Alberta Investment Management Corp

Alberta Investment Management Corp acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 206,532 shares of the biopharmaceutical company’s stock, valued at approximately $35,945,000.

Other institutional investors also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership lifted its holdings in shares of Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares during the period. Atika Capital Management LLC acquired a new stake in shares of Insmed during the third quarter worth $13,681,000. iA Global Asset Management Inc. raised its position in shares of Insmed by 15,973.5% during the fourth quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock worth $4,644,000 after purchasing an additional 26,516 shares during the period. Nordea Investment Management AB acquired a new position in Insmed during the fourth quarter valued at $3,492,000. Finally, Monashee Investment Management LLC acquired a new position in Insmed during the fourth quarter valued at $8,702,000.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at $7,065,016.14. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 2,370 shares of Insmed stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the sale, the chief operating officer directly owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This trade represents a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 160,482 shares of company stock valued at $24,438,193 over the last quarter. Corporate insiders own 2.10% of the company’s stock.

Insmed Trading Down 0.4%

INSM stock opened at $97.46 on Tuesday. The business has a fifty day moving average price of $123.25 and a 200 day moving average price of $150.13. The stock has a market capitalization of $21.12 billion, a price-to-earnings ratio of -16.95 and a beta of 0.79. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business’s revenue for the quarter was up 229.7% on a year-over-year basis. During the same period last year, the firm earned ($1.42) EPS. Analysts expect that Insmed, Inc. will post -2.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Guggenheim decreased their target price on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Raymond James Financial started coverage on Insmed in a research note on Friday, April 10th. They set an “outperform” rating and a $200.00 target price for the company. Barclays raised their price objective on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Finally, Roth Mkm reiterated a “buy” rating on shares of Insmed in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $212.50.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.